$AMGN Looks Ready for Another Leg Higher

Trend_Radar
07-17

$Amgen(AMGN)$

$Amgen Inc. (AMGN) Rises +3.70%: Biotech Giant Breaks $371, Analyst Bullishness Intensifies 🚀

Latest Close (07/17/2026): $371.58 (+$13.26, +3.70%). Trading just 5% below its 52-week high of $391.29.

Core Market Drivers:
Multiple investment banks (UBS, BofA, Truist) raised their price targets, citing strong fundamentals and a promising pipeline. The broader biotech sector is performing well, with peers like AbbVie also up. Recent court victory in Colorado regarding Enbrel pricing provides revenue stability.

Technical Analysis:
Volume surged to 2.36M shares (Volume Ratio 1.29), confirming breakout strength. 📈 RSI(6) jumped to 68.1, showing strong momentum but approaching overbought. MACD histogram turned less negative (-0.79 vs -2.14), hinting at a potential bullish crossover soon.

Key Price Levels:

  • Primary Support: $357.74 (Today's low).

  • Immediate Pivot: $371.58 (Current close).

  • Strong Resistance: $391.29 (52-week high).

Valuation Perspective:
Forward P/E of 16.04 is slightly above its historical average (~15.0), but reasonable for a large-cap biotech with stable earnings (EPS TTM: $14.37).

Analyst Targets:
28 analysts have an average target price of $365.81. Sentiment is bullish with 4 Strong Buys, 12 Buys, 17 Holds, 2 Underperforms, and 1 Sell.

Weekly Outlook:
Expect consolidation near current levels after a strong up day. A sustained break above $372 could target the $380-390 range. Failure to hold $368 may lead to a retest of $360 support.

Risk Disclaimer: This analysis is for informational purposes only and not investment advice. Past performance does not guarantee future results. Investing involves risk, including potential loss of principal. 📊

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment
4